{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:42:41Z","timestamp":1777480961856,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      Recent research has suggested that chronic alcohol exposure induces changes in the endocannabinoid system within the central nervous system and therefore could be an attractive target for better understanding and treating alcohol use disorder (AUD). Much of this research has centered around the CB\n                      <jats:sub>1<\/jats:sub>\n                      receptor and its endogenous partial agonist, the endocannabinoid anandamide, as the CB\n                      <jats:sub>1<\/jats:sub>\n                      receptor is densely expressed in brain regions involved in development and maintenance of addictive behaviors. In addition, recent evidence has suggested that chronic alcohol exposure induces changes in the modulation of endocannabinoid concentration and suggests that these changes may contribute to the motivation to abuse alcohol. Therefore, we performed a systematic literature review to evaluate how fatty acid amide hydrolase (FAAH), an enzyme that degrades anandamide, relates to the characteristics and biology of AUD, as well as how modulating FAAH through pharmacologic inhibition or genetic manipulation affects outcomes related to alcohol use and consumption.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A search strategy was developed using the terms \u201cendocannabinoids\u201d or \u201cdrug delivery systems\u201d and \u201calcohol dependence\u201d or \u201calcohol use disorder\u201d or \u201calcoholism\u201d and \u201cFatty Acid Amide Hydrolase\u201d and \u201cFAAH\u201d as text words and Medical Subject Headings (i.e., MeSH and EMTREE). We then used this search strategy on the electronic databases PubMed, Embase, and Web of Science.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We found 224 records; after removing repeated records (37%), articles that did not fit the topic question (47%), or were not primary research (4%), we included 26 for qualitative synthesis (12%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The literature clearly suggests that FAAH has a role in the biology and characteristics of AUD. FAAH inhibition seems especially promising as a target for alcohol withdrawal as it may lead to a reduction in symptoms, including anxiety and a reduction of alcohol intake reinstatement. However, decreased FAAH may also lead to reduced sensitivity to alcohol along with increased preference and intake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Modulation of FAAH is promising for therapeutic intervention of AUD, but requires more research. Pre-clinical studies have indicated that FAAH inhibition may reduce withdrawal characteristics, but may also exacerbate other characteristics of AUD outside of that period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2020.0158","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T16:41:26Z","timestamp":1617640886000},"page":"105-118","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Contribution of Fatty Acid Amide Hydrolase to Alcohol Use Disorder: A Systematic Review"],"prefix":"10.1177","volume":"6","author":[{"given":"Greta","family":"Niemela","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garth E.","family":"Terry","sequence":"additional","affiliation":[{"name":"Department of Psychiatry &amp; Behavioral Sciences, and Radiology, University of Washington School of Medicine, Seattle, Washington, USA."},{"name":"Department of Veterans Affairs, Puget Sound Health Care System, Mental Illness Research, Education, and Clinical Center (MIRECC), Seattle, Washington, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Alcohol Facts and Statistics. National Institute on Alcohol Abuse and Alcoholism U.S. Department of Health and Human Services. www.niaaa.nih.gov\/publications\/brochures-and-fact-sheets\/alcohol-facts-and-statistics. Published 2020."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14239"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-20825-1_3"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.11.020"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn4004"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100887"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.alcalc.a008368"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172b8bc"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1704-3"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14780"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.05.031"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddh216"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7395"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082235799"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12491"},{"key":"e_1_3_4_17_2","article-title":"Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB","volume":"45","author":"Best LM","unstructured":"Best LM, , Williams B, , Le Foll B, et al. Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. Neuropsychopharmacology. 45:1289\u20131296.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13210"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/YPG.0b013e32809913d8"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-013-0809-x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301034"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2010.00299.x"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2009.11.013"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2006.05.002"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.08.004"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20061898"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01557-7"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12160"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0055-3"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.05.002"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2013-1149"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12989"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.12.005"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301274"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04956.x"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12573"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1104-0"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12695"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v34.3.08"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2011.01686.x"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4691-9"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.11.044"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134408"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7120158"},{"key":"e_1_3_4_45_2","first-page":"2661","article-title":"Sex differences in alcohol use disorder","volume":"24","author":"Agabio R","year":"2016","unstructured":"Agabio R, , Pisanu C, , Gessa GL, et al. Sex differences in alcohol use disorder. Curr Med Chem. 2016; 24:2661\u20132670.","journal-title":"Curr Med Chem"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1643"},{"key":"e_1_3_4_47_2","first-page":"1","article-title":"The endocannabinoid hydrolase FAAH is an allosteric enzyme","volume":"10","author":"Dainese E","year":"2020","unstructured":"Dainese E, , Oddi S, , Simonetti M, et al. The endocannabinoid hydrolase FAAH is an allosteric enzyme. Sci Rep. 2020; 10:1\u201310.","journal-title":"Sci Rep"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14306"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.01.003"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2020.0158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2020.0158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2020.0158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:06Z","timestamp":1777385466000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2020.0158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4,1]]}},"alternative-id":["10.1089\/can.2020.0158"],"URL":"https:\/\/doi.org\/10.1089\/can.2020.0158","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}